Boehringer Ingelheim increases revenues by 3% in 2020 to €19.57 billion

Boehringer Ingelheim boosts 2020 net sales by 3% to €19.57 billion Boehringer Ingelheim boosts net sales in the Covid-19 year. The German drugmaker posted net sales of $23 billion (€19.57 billion), an increase of 3% year-on-year, the group explained in a statement. 

The group’s operating income rose to $5.44 billion (€4.62 billion) in 2020 from $4.45 billion (€3.78 billion) in 2019, while one-off gains from divestments supported operating income. Income after taxes saw a year-on-year increase of 12.5% to $3.6 billion (€3.06 billion). Cash flow from operating activities increased by $729 million (€619 million) to $4.67 billion (€3.96 billion). At the end of 2020, the equity ratio stood at 47%, the multinational explains.  

Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view. Born2Invest’s team of journalists gathers the most interesting business news in a single mobile application. It’s impossible to keep up with everything you’re interested in, but our companion app will help you keep track of the important news. Our app is being updated throughout the day.

Boehringer Ingelheim invested $4.4 billion (€3.7 billion) in R&D in 2020 

Boehringer Ingelheim increased its investments in research and development (R&D) significantly in 2020 in search of innovative drugs and treatments for diseases for which no satisfactory treatments are available. 

In particular, research efforts into potential treatments related to Covid-19 were accelerated. The company invested $4.4 billion (€3.7 billion) in R&D in 2020, up 7% year-on-year, representing the largest annual R&D investment in the pharma’s 136-year history.

In December 2020, the company announced together with the University Hospital Cologne (UKK), the University of Marburg (UMR) and the German Center for Infection Research (Dzif) the start of Phase I/IIa clinical research of BI 767551. It is the first Sars-Cov-2 neutralizing antibody administered by inhalation as a potential new therapeutic and prophylactic option to block the virus at the site of infection.  

The pharmaceutical company invested $1.24 billion (€1.05 billion) in tangible fixed assets in 2020 

The company invested $1.24 billion (€1.05 billion) in tangible fixed assets in 2020, including large-scale production facilities for biopharmaceuticals in Vienna, Austria, and the new biopharmaceutical drug development center in Biberach, Germany. Spending on tangible fixed assets decreased slightly compared with the all-time high in 2019 due to the partial delay in construction work caused by the pandemic. 

In Spain, Boehringer Ingelheim began its trajectory in 1952. Its corporate headquarters are currently located in Sant Cugat del Vallès (Barcelona), where it also has two pharmaceutical production plants. The company has more than 1,600 employees in Spain.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.